Celanese (CE) upgraded at Citigroup from Hold to Buy. $35 price target. Company is growing in China, which should also help keep costs down.
Celgene (CELG) rated new Buy at Stifel Nicolaus. $71 price target. Company has superior growth prospects.
Gilead Sciences (GILD) rated new Hold at Stifel Nicolaus. Valuation call, as the company is facing patent expirations.Idexx Laboratories (IDXX) rated new Market Perform at Leerink. Stock is already pricing in the company's organic growth potential. Skilled Healthcare Group (SKH) upgraded at Credit Suisse to Neutral from Underperform as the company agreed to a $50 million settlement in the Lavender case. The settlement was significantly lower than the Street's expectation, Credit Suisse said. Price target increased to $5 from $2. Teva Pharmaceutical (TEVA) upgraded at Oppenheimer from Perform to Outperform, Oppenheimer said. $65 price target. Effexor XR launch was strong and the company should post better earnings in the second half of 2010. Tellabs (TLAB) downgraded at Soleil from Buy to Hold. $8 price target. Estimates also cut, as the company is losing market share at Soleil. Valspar (VAL) was downgraded at Citigroup from Buy to Hold. $32 price target. Paint sales tailed off toward the end of summer, as the housing market soured.
STOCK COMMENTS / EPS CHANGESAltera (ALTR) estimates, target increased through 2011 at Citigroup. Company boosted guidance at its midquarter update. Buy rating and new $36 price target. Arris (ARRS) estimates, target lowered at UBS. Estimates cut through 2011. Cable CapEx spending could be slowing down, along with the broader economy. Neutral rating and new $9 price target. Allegheny Energy (AYE) numbers boosted at Citigroup. Shares of AYE now seen reaching $24, according to Citigroup. Estimates also upped, as the company is cutting costs and should see higher regulated earnings. Hold rating. Coca-Cola Enterprises (CCE) numbers raised at UBS. Shares of CCE now seen reaching $34, according to UBS. Estimates also increased, to match the company's new guidance. Buy rating. Chesapeake Midstream Partners (CHKM) estimates cut at Barclays. 2011 EPS estimate lowered to $1.51, 2010 held at $1.05. Chesapeake Midstream reported second-quarter results in line, Barclays said. Maintain Overweight rating and $26 target. Hasbro (HAS) target upped to $52 at Keybanc. Company held an upbeat investor meeting, and the Hub channel remains on track for launch. Buy rating. Las Vegas Sands (LVS) numbers raised at JP Morgan. Shares of LVS now seen reaching $36, according to JP Morgan. Estimates also increased, given better results in Singapore. Overweight rating.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV